Neumora Therapeutics, Inc. · NASDAQ:NMRA
Neumora Therapeutics — Q1 2025 Earnings Presentation
33 slides from Neumora Therapeutics's earnings presentation, May 12, 2025
Slide 1: Redefining Neuroscience Drug Development
Redefining Neuroscience Drug Development July 2025
Slide 2: Important Disclosures
Important Disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention to redefine neuroscience drug development by brin
Slide 3: Our Mission
Our Mission We are focused on redefining neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases 3
Slide 4: Redefining Neuroscience Drug Development
Redefining Neuroscience Drug Development Industry leading Built at scale with strong World-class team with CNS pipeline with long- balance sheet; $850M differentiated approach dated IP into the 2040s raised since 2021 Multiple value-creating Cash runway into Maximizing probability of clinical cataly
Slide 5: Neumora is Tackling Large Population Health Challenges
Neumora is Tackling Large Population Health Challenges Neumora’s clinical-stage pipeline has potential to reach up to ~30M+ patients with a robust IP runway into 2041+ Biggest Health Disorders Facing U.S.1 Patients Impacted (M) 0 20 40 60 80 100 120 140 Diabetes, Obesity & 30M+ Metabolic Disease Pat
Slide 6: Advancing a Leading Neuroscience Pipeline
Advancing a Leading Neuroscience Pipeline • Broad pipeline PROGRAM INDICATION MILESTONE Target/Mechanism U.S. Prevalence Preclinical Phase 1 Phase 2 Phase 3 Guidance addressing some of Clinical Programs the most prevalent Major Depressive Navacaprant Disorder KOASTAL-3, -2 topline data brain disease
Slide 7: MDD Represents a Major Population Health Challenge
MDD Represents a Major Population Health Challenge MDD is the leading 280M 21M 30 years cause of disability since a novel mechanism of people worldwide adults in the U.S. have MDD2; the worldwide1 have MDD1 median onset is ~32.5 years of age action was approved for MDD Many people have Many people h
Slide 8: The Role of Kappa Opioid Receptor Antagonism in MDD
The Role of Kappa Opioid Receptor Antagonism in MDD • The kappa opioid receptor (KOR) / dynorphin system is a well- characterized pathway, and results from preclinical studies support its potential to modulate depression, anhedonia, and anxiety • KOR system overactivation in response to stress and m
Slide 9: Near-term Clinical Development Plan Focused on MDD with Opportunity for Further Expansion
Near-term Clinical Development Plan Focused on MDD with Opportunity for Further Expansion Major Depressive Disorder KOASTAL-LT Three replicate, placebo-controlled, double-blind RCTs Open-label extension evaluating efficacy and safety of navacaprant in MDD trial evaluating long-term safety of navacap
Slide 10: KOASTAL Pivotal Study Design
KOASTAL Pivotal Study Design KOASTAL Pivotal Efficacy Studies Navacaprant 80 mg QD Opportunity R to enroll in 1:1 Placebo QD KOASTAL-LT Randomized, double-blind treatment Baseline WK WK WK WK 1 2 4 6 Key Efficacy Assessments KOASTAL-1, KOASTAL-2, KOASTAL-3 Summary • Adults ages 18 – 65 diagnosed wit
Slide 11: KOASTAL-1 Topline Data: Demographics and Baseline Characteristics
KOASTAL-1 Topline Data: Demographics and Baseline Characteristics Navacaprant Placebo Intent-to-Treat Population n = 191 N = 192 Age, mean (SD) 40.7 (14.0) 41.1 (13.2) Sex, n (%) Male 86 (45.0%) 86 (44.8%) Female 105 (55.0%) 106 (55.2%) Race, n (%) White 112 (58.6%) 127 (66.1%) Black or African Amer
Slide 12: KOASTAL-1 Topline Data: Primary & Key Secondary Endpoint
KOASTAL-1 Topline Data: Primary & Key Secondary Endpoint MADRS Total Score SHAPS Total Score Intent-to-Treat Population Intent-to-Treat Population 0 0 Navacaprant (n=191) Navacaprant (n=191) Placebo (n=192) -1 Placebo (n=192) -2 -4 Change From Baseline -2 Change From Baseline LS Mean Change (SE) LS
Slide 13: KOASTAL-1 Topline Data: Favorable Safety Profile Demonstrated
KOASTAL-1 Topline Data: Favorable Safety Profile Demonstrated Navacaprant was safe and generally well tolerated, with no serious adverse events reported TEAEs Incidence Placebo Navacaprant (>2% in either treatment group) n=192 n=191 • No signal for increased Preferred Terms n (%) n (%) suicidal idea
Slide 14: Optimizing KOASTAL-2 and -3 Phase Trials
Optimizing KOASTAL-2 and -3 Phase 3 Trials Topline data from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Site Selection Medical Monitoring Screening Tools Target Enrollment Adjusted clinical sites Using clinician-rated Verified Clinical Trial Option included in includ
Slide 15: NMRA-511 is a Best-in-Class Vasopressin 1a Receptor Antagonist
NMRA-511 is a Best-in-Class Vasopressin 1a Receptor Antagonist with Broad Potential Across Neuropsychiatric Disorders Rationale Vasopressin plays a role in the regulation of aggression, affiliation, stress and anxiety response Indication Agitation in Alzheimer’s disease Status Phase 1b study underwa
Slide 16: Alzheimer's Disease Agitation Represents Large Market Opportunity with Significant Unmet Need
Alzheimer’s Disease Agitation Represents Large Market Opportunity with Significant Unmet Need Agitation in Alzheimer’s disease impacts a significant portion of the U.S. population; that number is expected to increase as the population ages1 U.S. Adults with Alzheimer’s Disease (M)1 14 13M 13 12 >70%
Slide 17: Several Lines of Evidence Indicate that V1a Receptor Antagonists Have Therapeutic Potential
Several Lines of Evidence Indicate that V1a Receptor Antagonists Have Therapeutic Potential for Reducing Symptoms of Agitation The vasopressin system modulates social-emotional, Positive association between vasopressin and aggression anxiety and threat-related behaviors across species in people with
Slide 18: NMRA-511 Profile Supports Advancement into Alzheimer's Disease Agitation
NMRA-511 Profile Supports Advancement into Alzheimer’s Disease Agitation Best-in-Class Strong Pre-Clinical PK and Safety Data from Pharmacology1 Data2 Phase 1 Support Advancement1 • Highly potent at V1a • Robust pharmacodynamic (PD) • NMRA-511 was safe • High selectivity over V1b, V2, effect in rode
Slide 19: NMRA-511 Signal Seeking Study in Alzheimer's Disease Agitation
NMRA-511 Signal Seeking Study in Alzheimer’s Disease Agitation Part A: 2-Week Evaluation Period Part B: 8-Week Evaluation Period Enrolling People Enrolling Healthy Elderly Participants with Alzheimer’s Disease Agitation (ADA) NMRA-511 20 mg BID (n=6) NMRA-511 20 mg BID (n=44) R R 1:1 1:1 Placebo BID
Slide 20: M4 PAM Franchise: Differentiated M4R PAMs for Schizophrenia
M4 PAM Franchise: Differentiated M4R PAMs for Schizophrenia NMRA-861 Target Profile Pharmacology IP Neumora has multiple series Composition of matter patent of chemically distinct, highly extending to 2044+* selective M4 muscarinic receptor PAMs, including Epidemiology NMRA-861, designed for Estimat
Slide 21: An Optimized Muscarinic Drug Profile Would Include Selectivity and Potency in the CNS
An Optimized Muscarinic Drug Profile Would Include Selectivity and Potency in the CNS Preclinical data and clinical Non-selective muscarinic PAMs offer the benefits of data in acute schizophrenia agents are associated with a greater selectivity supports M4 as a driver of range of peripheral AEs anti
Slide 22: Emraclidine Receptor Occupancy Disconnected from Plasma Exposures
Emraclidine Receptor Occupancy Disconnected from Plasma Exposures Receptor Occupancy for Emraclidine in Humans Suggests the Compound has Limited Brain Exposure • In a human PET study, peripheral concentration of emraclidine shows dose linear response • However, CNS receptor occupancy unchanged when
Slide 23: NMRA-861 Has Potential Best-in-Class Potency and Optimized Brain Penetration
NMRA-861 Has Potential Best-in-Class Potency and Optimized Brain Penetration NMRA-8611 NMRA-M4R1 Emraclidine M4 EC50 6 nM 13 nM 26 nM (human; cAMP)1 NMRA-861 and –M4R potentially more potent than emraclidine across multiple assays M4 EC50 2 nM 8 nM 180 nM (human; Ca2+)1 NMRA-861 and –M4R are selecti
Slide 24: SAD/MAD Evaluating NMRA-861 in Healthy Adults and People with Stable Schizophrenia
SAD/MAD Evaluating NMRA-861 in Healthy Adults and People with Stable Schizophrenia SAD – Part 1 CSP Study Objectives Dose Cohortsa Participants Randomization 5 mg, 15 mg, 45mg, Part 1A Healthy adults 6:2 active:placebo 80 mg, final dose TBDb • Confirm once-daily dosing – based on PK profile in human
Slide 25: Pre-Clinical Pipeline of Four Novel Programs, Each with A Strong Biological Rationale
Pre-Clinical Pipeline of Four Novel Programs, Each with A Strong Biological Rationale NMRA-CK1δ NMRA-NMDA NMRA-NLRP3 NMRA-GCASE Focused on inhibiting the protein casein NMDA receptor hypofunction is a Focused on inhibiting the NLRP3 Focused on elevating activity of the kinase-1δ (CK1δ) to reduce lev
Slide 26: Redefining Neuroscience Drug Development
Redefining Neuroscience Drug Development Industry leading Built at scale with strong World-class team with CNS pipeline with long- balance sheet; $850M differentiated approach dated IP into the 2040s raised since 2021 Multiple value-creating Cash runway into Maximizing probability of clinical cataly
Slide 27: Appendix
Appendix 27
Slide 28: Led by Experienced Company Builders and Leading Neuroscience Drug Developers
Led by Experienced Company Builders and Leading Neuroscience Drug Developers Leadership Board of Directors Paul L. Berns Joshua Pinto, Ph.D. Bill Aurora, Pharm.D. Paul L. Berns Co-Founder, Chief Executive Officer & President Chief Operating & Development Officer Co-Founder, Chief Executive Officer,
Slide 29: KOASTAL-1 Topline Study Summary Results
KOASTAL-1 Topline Study Summary Results The KOASTAL-1 study enrolled 383 adult patients with Major Depressive Disorder (MDD) MADRS Total Score SHAPS Total Score Navacaprant Navacaprant Outcome Placebo LSMD Placebo LSMD 80 mg 80 mg ITT population CFB at Week -12.5 -12.5 0.0 -5.8 -5.5 -0.3 6 (Primary
Slide 30: Navacaprant Would Enter Large MDD Market with a Highly Differentiated Profile
Navacaprant Would Enter Large MDD Market with a Highly Differentiated Profile GROWTH IN ADDRESSABLE MDD MARKET EXPECTED IN-LINE WITH POPULATION GROWTH U.S. MDD diagnosed, pharmacologically treated prevalent of MDD patients across lines of therapy population (2018-41F) Millions of people 60-80% are t
Slide 31: Schizophrenia Market Supports Multiple Treatment Options
Schizophrenia Market Supports Multiple Treatment Options Historically the schizophrenia market has supported multiple branded products with similar MOAs, with new entrants driving higher overall market sales volume Sales of Branded 5-HT2 to D2 Receptor Antagonists (1995 – 2013) 12,000 Product Launch
Slide 32: Opportunity to Build a Leading Neuropsych Product Franchise
Opportunity to Build a Leading Neuropsych Product Franchise Potential for broad indication expansion in poorly served disorders with a novel mechanism Schizophrenia Additional Opportunities Opportunities Acute Schizophrenia Bipolar Depression Monotherapy Behavioral Disturbances Acute Schizophrenia i
Slide 33: © Neumora
© Neumora